Global Facial Injectables Market

Facial Injectables Comprehensive Study by Type (Collagen, Hyaluronic Acid (HA), Botulinum Toxin Type A, Calcium Hydroxylapatite (CaHA), Polymer Fillers), Application (Aesthetic Restoration, Dentistry, Reconstructive Surgery), End User (Hospitals, Ambulatory Surgical Centers, Cosmetic Centers, Dermatology Clinics, Physician Clinics) Players and Region - Global Market Outlook to 2030

Facial Injectables Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 11%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Facial Injectables
Facial Injectables refers to the treatment-related skin problems for facial rejuvenation and are used to as anti-ageing agents. The skin problem may arise due to aging, facial skin commences, losing its natural hydration and flexibility, which helps in supporting, shaping, and adding volume to face, thereby resulting into sagging of skin, deep lines, and wrinkles on the face. Facial Injectables can be used to plump thin lips, enhance shallow contours, soften facial creases and wrinkles and improve the appearance of recessed scars.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketEurope
UnitValue (USD Billion)
CAGR11.0%


The key players featured in this report offer wide range of facial injectable solutions such as dermal fillers or other aesthetic fillers. Out of which Allergan, Galdermal (Q-Med), Sinclair Pharma, Sanofi Aventis, IMEIK are leading in the global market for facial injectable segments.The companies operating in the Facial Injectable market are focusing on novel innovations in terms for the product design. Analyst at AMA Research estimates that United States and Chinese Players will contribute the maximum growth to Global Facial Injectables market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Allergan plc (Ireland), Galderma S.A. (Switzerland), Sinclair Pharma (United Kingdom), Zimmer Biomet (United States), Anika Therapeutics, Inc. (United States), Merz Pharma (Germany), Ipsen Pharma (France), Teoxane Laboratories (Switzerland), Prollenium Medical Technologies (Canada) and Suneva Medical, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are LG Life Sciences, Ltd. (LG Chem.) (South Korea), BohusBioTech AB (Sweden), Imeik Technology Development Co Ltd (China), Bloomage Freda Biopharm Co. LTD (China), Sanofi Aventis (France) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Facial Injectables market by Type (Collagen, Hyaluronic Acid (HA), Botulinum Toxin Type A, Calcium Hydroxylapatite (CaHA) and Polymer Fillers), Application (Aesthetic Restoration, Dentistry and Reconstructive Surgery) and Region.

On the basis of application, Aesthetic Restoration segment is dominating the market in the year 2023

On the basis of geography, the market of Facial Injectables has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Facial Injectables market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Non-Invasive Laser Surgeries, Lip, Nose and Jawline Fillers and Gender-Specific Facial Treatments

Market Growth Drivers:
Upcoming Innovations in Facial Rejuvenation Procedures, Possible Customization in Facial Injectable Treatments and Increased Patients Interest about rejuvenation

Challenges:
Controlling Post Surgery Infections, Minimizing Side Effects Facial Injectable Treatment and Developing Highly Accurate and more Beneficial Facial Injectables

Restraints:
Regular and Repetitive Treatments Needed, Negative Side Effects Require More Time to Resolve and Continues Treatments may cause skin weakness

Opportunities:
Growing Awareness About Non Invasive Facial Treatments, Increasing Disposable Incomes of the Consumers and Increasing Adoption of Less Painful Laser Surgeries

Market Leaders and their expansionary development strategies
In May 2023, Evolus has entered into a definitive agreement to be the exclusive US distributor of a line of five dermal fillers currently in late-stage development.
In March 2023, Galderma announced the launch of FACE by Galderma, an innovative aesthetic visualization tool powered by augmented reality (AR) that allows aesthetic professionals and patients to visualize injectable treatment results* at the planning stage before treatment begins. This innovative solution gives patients a simulated real-time "before and after" visual of what may be possible from an individualized treatment plan and may help alleviate patient concerns about injectable results.
The FD&C Act defines cosmetics by their intended use, as "articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance will come under cosmetics segment but the substances intended for a therapeutic use, such as treating or preventing skin disease, or to affect the structure or function of the body, it’s a drug " (FD&C Act, sec. 201(i) and (g)).

Key Target Audience
Facial Injectable Producers, Facial Injectable distributors and Traders, Hospitals and Other Research and Development Organisations, Government and Private Agencies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Collagen
  • Hyaluronic Acid (HA)
  • Botulinum Toxin Type A
  • Calcium Hydroxylapatite (CaHA)
  • Polymer Fillers
By Application
  • Aesthetic Restoration
  • Dentistry
  • Reconstructive Surgery
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Cosmetic Centers
  • Dermatology Clinics
  • Physician Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Upcoming Innovations in Facial Rejuvenation Procedures
      • 3.2.2. Possible Customization in Facial Injectable Treatments
      • 3.2.3. Increased Patients Interest about rejuvenation
    • 3.3. Market Challenges
      • 3.3.1. Controlling Post Surgery Infections
      • 3.3.2. Minimizing Side Effects Facial Injectable Treatment
      • 3.3.3. Developing Highly Accurate and more Beneficial Facial Injectables
    • 3.4. Market Trends
      • 3.4.1. Non-Invasive Laser Surgeries
      • 3.4.2. Lip, Nose and Jawline Fillers
      • 3.4.3. Gender-Specific Facial Treatments
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Facial Injectables, by Type, Application, End User and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Facial Injectables (Value)
      • 5.2.1. Global Facial Injectables by: Type (Value)
        • 5.2.1.1. Collagen
        • 5.2.1.2. Hyaluronic Acid (HA)
        • 5.2.1.3. Botulinum Toxin Type A
        • 5.2.1.4. Calcium Hydroxylapatite (CaHA)
        • 5.2.1.5. Polymer Fillers
      • 5.2.2. Global Facial Injectables by: Application (Value)
        • 5.2.2.1. Aesthetic Restoration
        • 5.2.2.2. Dentistry
        • 5.2.2.3. Reconstructive Surgery
      • 5.2.3. Global Facial Injectables by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Ambulatory Surgical Centers
        • 5.2.3.3. Cosmetic Centers
        • 5.2.3.4. Dermatology Clinics
        • 5.2.3.5. Physician Clinics
      • 5.2.4. Global Facial Injectables Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Facial Injectables (Volume)
      • 5.3.1. Global Facial Injectables by: Type (Volume)
        • 5.3.1.1. Collagen
        • 5.3.1.2. Hyaluronic Acid (HA)
        • 5.3.1.3. Botulinum Toxin Type A
        • 5.3.1.4. Calcium Hydroxylapatite (CaHA)
        • 5.3.1.5. Polymer Fillers
      • 5.3.2. Global Facial Injectables by: Application (Volume)
        • 5.3.2.1. Aesthetic Restoration
        • 5.3.2.2. Dentistry
        • 5.3.2.3. Reconstructive Surgery
      • 5.3.3. Global Facial Injectables by: End User (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Ambulatory Surgical Centers
        • 5.3.3.3. Cosmetic Centers
        • 5.3.3.4. Dermatology Clinics
        • 5.3.3.5. Physician Clinics
      • 5.3.4. Global Facial Injectables Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Facial Injectables (Price)
      • 5.4.1. Global Facial Injectables by: Type (Price)
  • 6. Facial Injectables: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan plc (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Galderma S.A. (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sinclair Pharma (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Zimmer Biomet (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Anika Therapeutics, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merz Pharma (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ipsen Pharma (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teoxane Laboratories (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Prollenium Medical Technologies (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Suneva Medical, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Facial Injectables Sale, by Type, Application, End User and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Facial Injectables (Value)
      • 7.2.1. Global Facial Injectables by: Type (Value)
        • 7.2.1.1. Collagen
        • 7.2.1.2. Hyaluronic Acid (HA)
        • 7.2.1.3. Botulinum Toxin Type A
        • 7.2.1.4. Calcium Hydroxylapatite (CaHA)
        • 7.2.1.5. Polymer Fillers
      • 7.2.2. Global Facial Injectables by: Application (Value)
        • 7.2.2.1. Aesthetic Restoration
        • 7.2.2.2. Dentistry
        • 7.2.2.3. Reconstructive Surgery
      • 7.2.3. Global Facial Injectables by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Ambulatory Surgical Centers
        • 7.2.3.3. Cosmetic Centers
        • 7.2.3.4. Dermatology Clinics
        • 7.2.3.5. Physician Clinics
      • 7.2.4. Global Facial Injectables Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Facial Injectables (Volume)
      • 7.3.1. Global Facial Injectables by: Type (Volume)
        • 7.3.1.1. Collagen
        • 7.3.1.2. Hyaluronic Acid (HA)
        • 7.3.1.3. Botulinum Toxin Type A
        • 7.3.1.4. Calcium Hydroxylapatite (CaHA)
        • 7.3.1.5. Polymer Fillers
      • 7.3.2. Global Facial Injectables by: Application (Volume)
        • 7.3.2.1. Aesthetic Restoration
        • 7.3.2.2. Dentistry
        • 7.3.2.3. Reconstructive Surgery
      • 7.3.3. Global Facial Injectables by: End User (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Ambulatory Surgical Centers
        • 7.3.3.3. Cosmetic Centers
        • 7.3.3.4. Dermatology Clinics
        • 7.3.3.5. Physician Clinics
      • 7.3.4. Global Facial Injectables Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Facial Injectables (Price)
      • 7.4.1. Global Facial Injectables by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Facial Injectables: by Type(USD Billion)
  • Table 2. Facial Injectables Collagen , by Region USD Billion (2018-2023)
  • Table 3. Facial Injectables Hyaluronic Acid (HA) , by Region USD Billion (2018-2023)
  • Table 4. Facial Injectables Botulinum Toxin Type A , by Region USD Billion (2018-2023)
  • Table 5. Facial Injectables Calcium Hydroxylapatite (CaHA) , by Region USD Billion (2018-2023)
  • Table 6. Facial Injectables Polymer Fillers , by Region USD Billion (2018-2023)
  • Table 7. Facial Injectables: by Application(USD Billion)
  • Table 8. Facial Injectables Aesthetic Restoration , by Region USD Billion (2018-2023)
  • Table 9. Facial Injectables Dentistry , by Region USD Billion (2018-2023)
  • Table 10. Facial Injectables Reconstructive Surgery , by Region USD Billion (2018-2023)
  • Table 11. Facial Injectables: by End User(USD Billion)
  • Table 12. Facial Injectables Hospitals , by Region USD Billion (2018-2023)
  • Table 13. Facial Injectables Ambulatory Surgical Centers , by Region USD Billion (2018-2023)
  • Table 14. Facial Injectables Cosmetic Centers , by Region USD Billion (2018-2023)
  • Table 15. Facial Injectables Dermatology Clinics , by Region USD Billion (2018-2023)
  • Table 16. Facial Injectables Physician Clinics , by Region USD Billion (2018-2023)
  • Table 17. South America Facial Injectables, by Country USD Billion (2018-2023)
  • Table 18. South America Facial Injectables, by Type USD Billion (2018-2023)
  • Table 19. South America Facial Injectables, by Application USD Billion (2018-2023)
  • Table 20. South America Facial Injectables, by End User USD Billion (2018-2023)
  • Table 21. Brazil Facial Injectables, by Type USD Billion (2018-2023)
  • Table 22. Brazil Facial Injectables, by Application USD Billion (2018-2023)
  • Table 23. Brazil Facial Injectables, by End User USD Billion (2018-2023)
  • Table 24. Argentina Facial Injectables, by Type USD Billion (2018-2023)
  • Table 25. Argentina Facial Injectables, by Application USD Billion (2018-2023)
  • Table 26. Argentina Facial Injectables, by End User USD Billion (2018-2023)
  • Table 27. Rest of South America Facial Injectables, by Type USD Billion (2018-2023)
  • Table 28. Rest of South America Facial Injectables, by Application USD Billion (2018-2023)
  • Table 29. Rest of South America Facial Injectables, by End User USD Billion (2018-2023)
  • Table 30. Asia Pacific Facial Injectables, by Country USD Billion (2018-2023)
  • Table 31. Asia Pacific Facial Injectables, by Type USD Billion (2018-2023)
  • Table 32. Asia Pacific Facial Injectables, by Application USD Billion (2018-2023)
  • Table 33. Asia Pacific Facial Injectables, by End User USD Billion (2018-2023)
  • Table 34. China Facial Injectables, by Type USD Billion (2018-2023)
  • Table 35. China Facial Injectables, by Application USD Billion (2018-2023)
  • Table 36. China Facial Injectables, by End User USD Billion (2018-2023)
  • Table 37. Japan Facial Injectables, by Type USD Billion (2018-2023)
  • Table 38. Japan Facial Injectables, by Application USD Billion (2018-2023)
  • Table 39. Japan Facial Injectables, by End User USD Billion (2018-2023)
  • Table 40. India Facial Injectables, by Type USD Billion (2018-2023)
  • Table 41. India Facial Injectables, by Application USD Billion (2018-2023)
  • Table 42. India Facial Injectables, by End User USD Billion (2018-2023)
  • Table 43. South Korea Facial Injectables, by Type USD Billion (2018-2023)
  • Table 44. South Korea Facial Injectables, by Application USD Billion (2018-2023)
  • Table 45. South Korea Facial Injectables, by End User USD Billion (2018-2023)
  • Table 46. Taiwan Facial Injectables, by Type USD Billion (2018-2023)
  • Table 47. Taiwan Facial Injectables, by Application USD Billion (2018-2023)
  • Table 48. Taiwan Facial Injectables, by End User USD Billion (2018-2023)
  • Table 49. Australia Facial Injectables, by Type USD Billion (2018-2023)
  • Table 50. Australia Facial Injectables, by Application USD Billion (2018-2023)
  • Table 51. Australia Facial Injectables, by End User USD Billion (2018-2023)
  • Table 52. Rest of Asia-Pacific Facial Injectables, by Type USD Billion (2018-2023)
  • Table 53. Rest of Asia-Pacific Facial Injectables, by Application USD Billion (2018-2023)
  • Table 54. Rest of Asia-Pacific Facial Injectables, by End User USD Billion (2018-2023)
  • Table 55. Europe Facial Injectables, by Country USD Billion (2018-2023)
  • Table 56. Europe Facial Injectables, by Type USD Billion (2018-2023)
  • Table 57. Europe Facial Injectables, by Application USD Billion (2018-2023)
  • Table 58. Europe Facial Injectables, by End User USD Billion (2018-2023)
  • Table 59. Germany Facial Injectables, by Type USD Billion (2018-2023)
  • Table 60. Germany Facial Injectables, by Application USD Billion (2018-2023)
  • Table 61. Germany Facial Injectables, by End User USD Billion (2018-2023)
  • Table 62. France Facial Injectables, by Type USD Billion (2018-2023)
  • Table 63. France Facial Injectables, by Application USD Billion (2018-2023)
  • Table 64. France Facial Injectables, by End User USD Billion (2018-2023)
  • Table 65. Italy Facial Injectables, by Type USD Billion (2018-2023)
  • Table 66. Italy Facial Injectables, by Application USD Billion (2018-2023)
  • Table 67. Italy Facial Injectables, by End User USD Billion (2018-2023)
  • Table 68. United Kingdom Facial Injectables, by Type USD Billion (2018-2023)
  • Table 69. United Kingdom Facial Injectables, by Application USD Billion (2018-2023)
  • Table 70. United Kingdom Facial Injectables, by End User USD Billion (2018-2023)
  • Table 71. Netherlands Facial Injectables, by Type USD Billion (2018-2023)
  • Table 72. Netherlands Facial Injectables, by Application USD Billion (2018-2023)
  • Table 73. Netherlands Facial Injectables, by End User USD Billion (2018-2023)
  • Table 74. Rest of Europe Facial Injectables, by Type USD Billion (2018-2023)
  • Table 75. Rest of Europe Facial Injectables, by Application USD Billion (2018-2023)
  • Table 76. Rest of Europe Facial Injectables, by End User USD Billion (2018-2023)
  • Table 77. MEA Facial Injectables, by Country USD Billion (2018-2023)
  • Table 78. MEA Facial Injectables, by Type USD Billion (2018-2023)
  • Table 79. MEA Facial Injectables, by Application USD Billion (2018-2023)
  • Table 80. MEA Facial Injectables, by End User USD Billion (2018-2023)
  • Table 81. Middle East Facial Injectables, by Type USD Billion (2018-2023)
  • Table 82. Middle East Facial Injectables, by Application USD Billion (2018-2023)
  • Table 83. Middle East Facial Injectables, by End User USD Billion (2018-2023)
  • Table 84. Africa Facial Injectables, by Type USD Billion (2018-2023)
  • Table 85. Africa Facial Injectables, by Application USD Billion (2018-2023)
  • Table 86. Africa Facial Injectables, by End User USD Billion (2018-2023)
  • Table 87. North America Facial Injectables, by Country USD Billion (2018-2023)
  • Table 88. North America Facial Injectables, by Type USD Billion (2018-2023)
  • Table 89. North America Facial Injectables, by Application USD Billion (2018-2023)
  • Table 90. North America Facial Injectables, by End User USD Billion (2018-2023)
  • Table 91. United States Facial Injectables, by Type USD Billion (2018-2023)
  • Table 92. United States Facial Injectables, by Application USD Billion (2018-2023)
  • Table 93. United States Facial Injectables, by End User USD Billion (2018-2023)
  • Table 94. Canada Facial Injectables, by Type USD Billion (2018-2023)
  • Table 95. Canada Facial Injectables, by Application USD Billion (2018-2023)
  • Table 96. Canada Facial Injectables, by End User USD Billion (2018-2023)
  • Table 97. Mexico Facial Injectables, by Type USD Billion (2018-2023)
  • Table 98. Mexico Facial Injectables, by Application USD Billion (2018-2023)
  • Table 99. Mexico Facial Injectables, by End User USD Billion (2018-2023)
  • Table 100. Facial Injectables Sales: by Type(K Units)
  • Table 101. Facial Injectables Sales Collagen , by Region K Units (2018-2023)
  • Table 102. Facial Injectables Sales Hyaluronic Acid (HA) , by Region K Units (2018-2023)
  • Table 103. Facial Injectables Sales Botulinum Toxin Type A , by Region K Units (2018-2023)
  • Table 104. Facial Injectables Sales Calcium Hydroxylapatite (CaHA) , by Region K Units (2018-2023)
  • Table 105. Facial Injectables Sales Polymer Fillers , by Region K Units (2018-2023)
  • Table 106. Facial Injectables Sales: by Application(K Units)
  • Table 107. Facial Injectables Sales Aesthetic Restoration , by Region K Units (2018-2023)
  • Table 108. Facial Injectables Sales Dentistry , by Region K Units (2018-2023)
  • Table 109. Facial Injectables Sales Reconstructive Surgery , by Region K Units (2018-2023)
  • Table 110. Facial Injectables Sales: by End User(K Units)
  • Table 111. Facial Injectables Sales Hospitals , by Region K Units (2018-2023)
  • Table 112. Facial Injectables Sales Ambulatory Surgical Centers , by Region K Units (2018-2023)
  • Table 113. Facial Injectables Sales Cosmetic Centers , by Region K Units (2018-2023)
  • Table 114. Facial Injectables Sales Dermatology Clinics , by Region K Units (2018-2023)
  • Table 115. Facial Injectables Sales Physician Clinics , by Region K Units (2018-2023)
  • Table 116. South America Facial Injectables Sales, by Country K Units (2018-2023)
  • Table 117. South America Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 118. South America Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 119. South America Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 120. Brazil Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 121. Brazil Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 122. Brazil Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 123. Argentina Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 124. Argentina Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 125. Argentina Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 126. Rest of South America Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 127. Rest of South America Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 128. Rest of South America Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 129. Asia Pacific Facial Injectables Sales, by Country K Units (2018-2023)
  • Table 130. Asia Pacific Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 131. Asia Pacific Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 132. Asia Pacific Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 133. China Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 134. China Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 135. China Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 136. Japan Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 137. Japan Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 138. Japan Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 139. India Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 140. India Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 141. India Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 142. South Korea Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 143. South Korea Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 144. South Korea Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 145. Taiwan Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 146. Taiwan Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 147. Taiwan Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 148. Australia Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 149. Australia Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 150. Australia Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 151. Rest of Asia-Pacific Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 152. Rest of Asia-Pacific Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 153. Rest of Asia-Pacific Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 154. Europe Facial Injectables Sales, by Country K Units (2018-2023)
  • Table 155. Europe Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 156. Europe Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 157. Europe Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 158. Germany Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 159. Germany Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 160. Germany Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 161. France Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 162. France Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 163. France Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 164. Italy Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 165. Italy Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 166. Italy Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 167. United Kingdom Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 168. United Kingdom Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 169. United Kingdom Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 170. Netherlands Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 171. Netherlands Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 172. Netherlands Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 173. Rest of Europe Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 174. Rest of Europe Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 175. Rest of Europe Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 176. MEA Facial Injectables Sales, by Country K Units (2018-2023)
  • Table 177. MEA Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 178. MEA Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 179. MEA Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 180. Middle East Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 181. Middle East Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 182. Middle East Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 183. Africa Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 184. Africa Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 185. Africa Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 186. North America Facial Injectables Sales, by Country K Units (2018-2023)
  • Table 187. North America Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 188. North America Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 189. North America Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 190. United States Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 191. United States Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 192. United States Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 193. Canada Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 194. Canada Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 195. Canada Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 196. Mexico Facial Injectables Sales, by Type K Units (2018-2023)
  • Table 197. Mexico Facial Injectables Sales, by Application K Units (2018-2023)
  • Table 198. Mexico Facial Injectables Sales, by End User K Units (2018-2023)
  • Table 199. Facial Injectables: by Type(USD/Units)
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Facial Injectables: by Type(USD Billion)
  • Table 211. Facial Injectables Collagen , by Region USD Billion (2025-2030)
  • Table 212. Facial Injectables Hyaluronic Acid (HA) , by Region USD Billion (2025-2030)
  • Table 213. Facial Injectables Botulinum Toxin Type A , by Region USD Billion (2025-2030)
  • Table 214. Facial Injectables Calcium Hydroxylapatite (CaHA) , by Region USD Billion (2025-2030)
  • Table 215. Facial Injectables Polymer Fillers , by Region USD Billion (2025-2030)
  • Table 216. Facial Injectables: by Application(USD Billion)
  • Table 217. Facial Injectables Aesthetic Restoration , by Region USD Billion (2025-2030)
  • Table 218. Facial Injectables Dentistry , by Region USD Billion (2025-2030)
  • Table 219. Facial Injectables Reconstructive Surgery , by Region USD Billion (2025-2030)
  • Table 220. Facial Injectables: by End User(USD Billion)
  • Table 221. Facial Injectables Hospitals , by Region USD Billion (2025-2030)
  • Table 222. Facial Injectables Ambulatory Surgical Centers , by Region USD Billion (2025-2030)
  • Table 223. Facial Injectables Cosmetic Centers , by Region USD Billion (2025-2030)
  • Table 224. Facial Injectables Dermatology Clinics , by Region USD Billion (2025-2030)
  • Table 225. Facial Injectables Physician Clinics , by Region USD Billion (2025-2030)
  • Table 226. South America Facial Injectables, by Country USD Billion (2025-2030)
  • Table 227. South America Facial Injectables, by Type USD Billion (2025-2030)
  • Table 228. South America Facial Injectables, by Application USD Billion (2025-2030)
  • Table 229. South America Facial Injectables, by End User USD Billion (2025-2030)
  • Table 230. Brazil Facial Injectables, by Type USD Billion (2025-2030)
  • Table 231. Brazil Facial Injectables, by Application USD Billion (2025-2030)
  • Table 232. Brazil Facial Injectables, by End User USD Billion (2025-2030)
  • Table 233. Argentina Facial Injectables, by Type USD Billion (2025-2030)
  • Table 234. Argentina Facial Injectables, by Application USD Billion (2025-2030)
  • Table 235. Argentina Facial Injectables, by End User USD Billion (2025-2030)
  • Table 236. Rest of South America Facial Injectables, by Type USD Billion (2025-2030)
  • Table 237. Rest of South America Facial Injectables, by Application USD Billion (2025-2030)
  • Table 238. Rest of South America Facial Injectables, by End User USD Billion (2025-2030)
  • Table 239. Asia Pacific Facial Injectables, by Country USD Billion (2025-2030)
  • Table 240. Asia Pacific Facial Injectables, by Type USD Billion (2025-2030)
  • Table 241. Asia Pacific Facial Injectables, by Application USD Billion (2025-2030)
  • Table 242. Asia Pacific Facial Injectables, by End User USD Billion (2025-2030)
  • Table 243. China Facial Injectables, by Type USD Billion (2025-2030)
  • Table 244. China Facial Injectables, by Application USD Billion (2025-2030)
  • Table 245. China Facial Injectables, by End User USD Billion (2025-2030)
  • Table 246. Japan Facial Injectables, by Type USD Billion (2025-2030)
  • Table 247. Japan Facial Injectables, by Application USD Billion (2025-2030)
  • Table 248. Japan Facial Injectables, by End User USD Billion (2025-2030)
  • Table 249. India Facial Injectables, by Type USD Billion (2025-2030)
  • Table 250. India Facial Injectables, by Application USD Billion (2025-2030)
  • Table 251. India Facial Injectables, by End User USD Billion (2025-2030)
  • Table 252. South Korea Facial Injectables, by Type USD Billion (2025-2030)
  • Table 253. South Korea Facial Injectables, by Application USD Billion (2025-2030)
  • Table 254. South Korea Facial Injectables, by End User USD Billion (2025-2030)
  • Table 255. Taiwan Facial Injectables, by Type USD Billion (2025-2030)
  • Table 256. Taiwan Facial Injectables, by Application USD Billion (2025-2030)
  • Table 257. Taiwan Facial Injectables, by End User USD Billion (2025-2030)
  • Table 258. Australia Facial Injectables, by Type USD Billion (2025-2030)
  • Table 259. Australia Facial Injectables, by Application USD Billion (2025-2030)
  • Table 260. Australia Facial Injectables, by End User USD Billion (2025-2030)
  • Table 261. Rest of Asia-Pacific Facial Injectables, by Type USD Billion (2025-2030)
  • Table 262. Rest of Asia-Pacific Facial Injectables, by Application USD Billion (2025-2030)
  • Table 263. Rest of Asia-Pacific Facial Injectables, by End User USD Billion (2025-2030)
  • Table 264. Europe Facial Injectables, by Country USD Billion (2025-2030)
  • Table 265. Europe Facial Injectables, by Type USD Billion (2025-2030)
  • Table 266. Europe Facial Injectables, by Application USD Billion (2025-2030)
  • Table 267. Europe Facial Injectables, by End User USD Billion (2025-2030)
  • Table 268. Germany Facial Injectables, by Type USD Billion (2025-2030)
  • Table 269. Germany Facial Injectables, by Application USD Billion (2025-2030)
  • Table 270. Germany Facial Injectables, by End User USD Billion (2025-2030)
  • Table 271. France Facial Injectables, by Type USD Billion (2025-2030)
  • Table 272. France Facial Injectables, by Application USD Billion (2025-2030)
  • Table 273. France Facial Injectables, by End User USD Billion (2025-2030)
  • Table 274. Italy Facial Injectables, by Type USD Billion (2025-2030)
  • Table 275. Italy Facial Injectables, by Application USD Billion (2025-2030)
  • Table 276. Italy Facial Injectables, by End User USD Billion (2025-2030)
  • Table 277. United Kingdom Facial Injectables, by Type USD Billion (2025-2030)
  • Table 278. United Kingdom Facial Injectables, by Application USD Billion (2025-2030)
  • Table 279. United Kingdom Facial Injectables, by End User USD Billion (2025-2030)
  • Table 280. Netherlands Facial Injectables, by Type USD Billion (2025-2030)
  • Table 281. Netherlands Facial Injectables, by Application USD Billion (2025-2030)
  • Table 282. Netherlands Facial Injectables, by End User USD Billion (2025-2030)
  • Table 283. Rest of Europe Facial Injectables, by Type USD Billion (2025-2030)
  • Table 284. Rest of Europe Facial Injectables, by Application USD Billion (2025-2030)
  • Table 285. Rest of Europe Facial Injectables, by End User USD Billion (2025-2030)
  • Table 286. MEA Facial Injectables, by Country USD Billion (2025-2030)
  • Table 287. MEA Facial Injectables, by Type USD Billion (2025-2030)
  • Table 288. MEA Facial Injectables, by Application USD Billion (2025-2030)
  • Table 289. MEA Facial Injectables, by End User USD Billion (2025-2030)
  • Table 290. Middle East Facial Injectables, by Type USD Billion (2025-2030)
  • Table 291. Middle East Facial Injectables, by Application USD Billion (2025-2030)
  • Table 292. Middle East Facial Injectables, by End User USD Billion (2025-2030)
  • Table 293. Africa Facial Injectables, by Type USD Billion (2025-2030)
  • Table 294. Africa Facial Injectables, by Application USD Billion (2025-2030)
  • Table 295. Africa Facial Injectables, by End User USD Billion (2025-2030)
  • Table 296. North America Facial Injectables, by Country USD Billion (2025-2030)
  • Table 297. North America Facial Injectables, by Type USD Billion (2025-2030)
  • Table 298. North America Facial Injectables, by Application USD Billion (2025-2030)
  • Table 299. North America Facial Injectables, by End User USD Billion (2025-2030)
  • Table 300. United States Facial Injectables, by Type USD Billion (2025-2030)
  • Table 301. United States Facial Injectables, by Application USD Billion (2025-2030)
  • Table 302. United States Facial Injectables, by End User USD Billion (2025-2030)
  • Table 303. Canada Facial Injectables, by Type USD Billion (2025-2030)
  • Table 304. Canada Facial Injectables, by Application USD Billion (2025-2030)
  • Table 305. Canada Facial Injectables, by End User USD Billion (2025-2030)
  • Table 306. Mexico Facial Injectables, by Type USD Billion (2025-2030)
  • Table 307. Mexico Facial Injectables, by Application USD Billion (2025-2030)
  • Table 308. Mexico Facial Injectables, by End User USD Billion (2025-2030)
  • Table 309. Facial Injectables Sales: by Type(K Units)
  • Table 310. Facial Injectables Sales Collagen , by Region K Units (2025-2030)
  • Table 311. Facial Injectables Sales Hyaluronic Acid (HA) , by Region K Units (2025-2030)
  • Table 312. Facial Injectables Sales Botulinum Toxin Type A , by Region K Units (2025-2030)
  • Table 313. Facial Injectables Sales Calcium Hydroxylapatite (CaHA) , by Region K Units (2025-2030)
  • Table 314. Facial Injectables Sales Polymer Fillers , by Region K Units (2025-2030)
  • Table 315. Facial Injectables Sales: by Application(K Units)
  • Table 316. Facial Injectables Sales Aesthetic Restoration , by Region K Units (2025-2030)
  • Table 317. Facial Injectables Sales Dentistry , by Region K Units (2025-2030)
  • Table 318. Facial Injectables Sales Reconstructive Surgery , by Region K Units (2025-2030)
  • Table 319. Facial Injectables Sales: by End User(K Units)
  • Table 320. Facial Injectables Sales Hospitals , by Region K Units (2025-2030)
  • Table 321. Facial Injectables Sales Ambulatory Surgical Centers , by Region K Units (2025-2030)
  • Table 322. Facial Injectables Sales Cosmetic Centers , by Region K Units (2025-2030)
  • Table 323. Facial Injectables Sales Dermatology Clinics , by Region K Units (2025-2030)
  • Table 324. Facial Injectables Sales Physician Clinics , by Region K Units (2025-2030)
  • Table 325. South America Facial Injectables Sales, by Country K Units (2025-2030)
  • Table 326. South America Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 327. South America Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 328. South America Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 329. Brazil Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 330. Brazil Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 331. Brazil Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 332. Argentina Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 333. Argentina Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 334. Argentina Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 335. Rest of South America Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 336. Rest of South America Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 337. Rest of South America Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 338. Asia Pacific Facial Injectables Sales, by Country K Units (2025-2030)
  • Table 339. Asia Pacific Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 340. Asia Pacific Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 341. Asia Pacific Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 342. China Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 343. China Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 344. China Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 345. Japan Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 346. Japan Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 347. Japan Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 348. India Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 349. India Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 350. India Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 351. South Korea Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 352. South Korea Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 353. South Korea Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 354. Taiwan Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 355. Taiwan Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 356. Taiwan Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 357. Australia Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 358. Australia Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 359. Australia Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 360. Rest of Asia-Pacific Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 361. Rest of Asia-Pacific Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 362. Rest of Asia-Pacific Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 363. Europe Facial Injectables Sales, by Country K Units (2025-2030)
  • Table 364. Europe Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 365. Europe Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 366. Europe Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 367. Germany Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 368. Germany Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 369. Germany Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 370. France Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 371. France Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 372. France Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 373. Italy Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 374. Italy Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 375. Italy Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 376. United Kingdom Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 377. United Kingdom Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 378. United Kingdom Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 379. Netherlands Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 380. Netherlands Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 381. Netherlands Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 382. Rest of Europe Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 383. Rest of Europe Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 384. Rest of Europe Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 385. MEA Facial Injectables Sales, by Country K Units (2025-2030)
  • Table 386. MEA Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 387. MEA Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 388. MEA Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 389. Middle East Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 390. Middle East Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 391. Middle East Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 392. Africa Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 393. Africa Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 394. Africa Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 395. North America Facial Injectables Sales, by Country K Units (2025-2030)
  • Table 396. North America Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 397. North America Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 398. North America Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 399. United States Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 400. United States Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 401. United States Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 402. Canada Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 403. Canada Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 404. Canada Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 405. Mexico Facial Injectables Sales, by Type K Units (2025-2030)
  • Table 406. Mexico Facial Injectables Sales, by Application K Units (2025-2030)
  • Table 407. Mexico Facial Injectables Sales, by End User K Units (2025-2030)
  • Table 408. Facial Injectables: by Type(USD/Units)
  • Table 409. Research Programs/Design for This Report
  • Table 410. Key Data Information from Secondary Sources
  • Table 411. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Facial Injectables: by Type USD Billion (2018-2023)
  • Figure 5. Global Facial Injectables: by Application USD Billion (2018-2023)
  • Figure 6. Global Facial Injectables: by End User USD Billion (2018-2023)
  • Figure 7. South America Facial Injectables Share (%), by Country
  • Figure 8. Asia Pacific Facial Injectables Share (%), by Country
  • Figure 9. Europe Facial Injectables Share (%), by Country
  • Figure 10. MEA Facial Injectables Share (%), by Country
  • Figure 11. North America Facial Injectables Share (%), by Country
  • Figure 12. Global Facial Injectables: by Type K Units (2018-2023)
  • Figure 13. Global Facial Injectables: by Application K Units (2018-2023)
  • Figure 14. Global Facial Injectables: by End User K Units (2018-2023)
  • Figure 15. South America Facial Injectables Share (%), by Country
  • Figure 16. Asia Pacific Facial Injectables Share (%), by Country
  • Figure 17. Europe Facial Injectables Share (%), by Country
  • Figure 18. MEA Facial Injectables Share (%), by Country
  • Figure 19. North America Facial Injectables Share (%), by Country
  • Figure 20. Global Facial Injectables: by Type USD/Units (2018-2023)
  • Figure 21. Global Facial Injectables share by Players 2023 (%)
  • Figure 22. Global Facial Injectables share by Players (Top 3) 2023(%)
  • Figure 23. Global Facial Injectables share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 26. Allergan plc (Ireland) Revenue: by Geography 2023
  • Figure 27. Galderma S.A. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Galderma S.A. (Switzerland) Revenue: by Geography 2023
  • Figure 29. Sinclair Pharma (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. Sinclair Pharma (United Kingdom) Revenue: by Geography 2023
  • Figure 31. Zimmer Biomet (United States) Revenue, Net Income and Gross profit
  • Figure 32. Zimmer Biomet (United States) Revenue: by Geography 2023
  • Figure 33. Anika Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Anika Therapeutics, Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Merz Pharma (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Merz Pharma (Germany) Revenue: by Geography 2023
  • Figure 37. Ipsen Pharma (France) Revenue, Net Income and Gross profit
  • Figure 38. Ipsen Pharma (France) Revenue: by Geography 2023
  • Figure 39. Teoxane Laboratories (Switzerland) Revenue, Net Income and Gross profit
  • Figure 40. Teoxane Laboratories (Switzerland) Revenue: by Geography 2023
  • Figure 41. Prollenium Medical Technologies (Canada) Revenue, Net Income and Gross profit
  • Figure 42. Prollenium Medical Technologies (Canada) Revenue: by Geography 2023
  • Figure 43. Suneva Medical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Suneva Medical, Inc. (United States) Revenue: by Geography 2023
  • Figure 45. Global Facial Injectables: by Type USD Billion (2025-2030)
  • Figure 46. Global Facial Injectables: by Application USD Billion (2025-2030)
  • Figure 47. Global Facial Injectables: by End User USD Billion (2025-2030)
  • Figure 48. South America Facial Injectables Share (%), by Country
  • Figure 49. Asia Pacific Facial Injectables Share (%), by Country
  • Figure 50. Europe Facial Injectables Share (%), by Country
  • Figure 51. MEA Facial Injectables Share (%), by Country
  • Figure 52. North America Facial Injectables Share (%), by Country
  • Figure 53. Global Facial Injectables: by Type K Units (2025-2030)
  • Figure 54. Global Facial Injectables: by Application K Units (2025-2030)
  • Figure 55. Global Facial Injectables: by End User K Units (2025-2030)
  • Figure 56. South America Facial Injectables Share (%), by Country
  • Figure 57. Asia Pacific Facial Injectables Share (%), by Country
  • Figure 58. Europe Facial Injectables Share (%), by Country
  • Figure 59. MEA Facial Injectables Share (%), by Country
  • Figure 60. North America Facial Injectables Share (%), by Country
  • Figure 61. Global Facial Injectables: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Allergan plc (Ireland)
  • Galderma S.A. (Switzerland)
  • Sinclair Pharma (United Kingdom)
  • Zimmer Biomet (United States)
  • Anika Therapeutics, Inc. (United States)
  • Merz Pharma (Germany)
  • Ipsen Pharma (France)
  • Teoxane Laboratories (Switzerland)
  • Prollenium Medical Technologies (Canada)
  • Suneva Medical, Inc. (United States)
Additional players considered in the study are as follows:
LG Life Sciences, Ltd. (LG Chem.) (South Korea) , BohusBioTech AB (Sweden) , Imeik Technology Development Co Ltd (China) , Bloomage Freda Biopharm Co. LTD (China) , Sanofi Aventis (France) , Others
Select User Access Type

Key Highlights of Report


Mar 2024 210 Pages 76 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Facial Injectables Market Quantitative research analysis
Global Facial Injectables Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Allergan plc (Ireland), Galderma S.A. (Switzerland), Sinclair Pharma (United Kingdom), Zimmer Biomet (United States), Anika Therapeutics, Inc. (United States), Merz Pharma (Germany), Ipsen Pharma (France), Teoxane Laboratories (Switzerland), Prollenium Medical Technologies (Canada) and Suneva Medical, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Non-Invasive Laser Surgeries " is seen as one of major influencing trends for Facial Injectables Market during projected period 2023-2030.
The Facial Injectables market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Facial Injectables Market Report?

Have a Query? Click Here

Other Related Reports

Vaccine Delivery Devices Comprehensive Study by Type (Syringes, Jet Injectors, Other Devices), Application (Intradermal Vaccination, Intramuscular Vaccination, Subcutaneous Vaccination, Others), Admi...
$ 3450
Cardiac Catheters Comprehensive Study by Type (Diagnostic Cardiac Catheters, Guiding Cardiac Catheters), Application (Diabetes, Renal failure, Cardiovascular diseases, Minimally invasive), Material (...
$ 3650
Perfusion Systems Comprehensive Study by Type (Bioreactor Perfusion Systems, Microfluidic Perfusion Systems, Gravity Or Pressure-Driven Perfusion Systems, Small-Mammal Organ Perfusion Systems), Appli...
$ 3750
Invisalign System Comprehensive Study by Type (Mouth Invisalign System, Skeleton Invisalign System), Application (Children, Adults, Old Men), Distribution Channel (Direct Sale, Laboratories, Other) P...
$ 3500
Gynecology Surgical Instruments Comprehensive Study by Type (Forceps(Allis Forceps, Artery Forceps, Other Forceps), Vaginal Speculums {Sims, Cusco, Other (Graves, Pediatric, and Pederson)}, Scissors,...
$ 3750
Emergency Evacuation Chair Comprehensive Study by Type (Standard Chai, Stair Climbing Chair, Sled Evacuation Chair, Multi-purpose Chair), Application (Household, Commercial Building, Transportation, ...
$ 3650